Analysts Anticipate ADMA Biologics Inc (ADMA) Will Post Quarterly Sales of $5.53 Million

Brokerages expect ADMA Biologics Inc (NASDAQ:ADMA) to post $5.53 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for ADMA Biologics’ earnings. The highest sales estimate is $6.00 million and the lowest is $5.06 million. ADMA Biologics reported sales of $3.40 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 62.6%. The company is expected to report its next earnings results on Friday, August 10th.

According to Zacks, analysts expect that ADMA Biologics will report full-year sales of $22.71 million for the current fiscal year, with estimates ranging from $22.41 million to $23.00 million. For the next financial year, analysts forecast that the firm will post sales of $80.71 million per share, with estimates ranging from $50.33 million to $111.10 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow ADMA Biologics.

Several research firms have recently issued reports on ADMA. LADENBURG THALM/SH SH reduced their target price on shares of ADMA Biologics to $7.50 and set a “buy” rating for the company in a research note on Wednesday. ValuEngine upgraded shares of ADMA Biologics from a “sell” rating to a “hold” rating in a research note on Monday, May 14th. Finally, Maxim Group set a $10.00 target price on shares of ADMA Biologics and gave the stock a “buy” rating in a research note on Tuesday, April 24th.

ADMA stock traded up $0.08 during midday trading on Monday, reaching $4.87. 15,714 shares of the company’s stock traded hands, compared to its average volume of 141,609. The firm has a market capitalization of $210.27 million, a PE ratio of -2.55 and a beta of 2.11. The company has a current ratio of 4.92, a quick ratio of 3.60 and a debt-to-equity ratio of 1.76. ADMA Biologics has a 52 week low of $2.01 and a 52 week high of $5.70.

In related news, CEO Adam S. Grossman purchased 52,301 shares of ADMA Biologics stock in a transaction that occurred on Friday, June 8th. The stock was bought at an average price of $4.78 per share, for a total transaction of $249,998.78. Following the completion of the transaction, the chief executive officer now owns 32,527 shares in the company, valued at $155,479.06. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jerrold B. Grossman purchased 20,921 shares of ADMA Biologics stock in a transaction that occurred on Friday, June 8th. The shares were bought at an average price of $4.78 per share, with a total value of $100,002.38. Following the transaction, the director now owns 98,007 shares of the company’s stock, valued at approximately $468,473.46. The disclosure for this purchase can be found here. In the last quarter, insiders bought 78,222 shares of company stock valued at $373,901. Company insiders own 16.90% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of ADMA. Geode Capital Management LLC grew its position in ADMA Biologics by 420.3% during the fourth quarter. Geode Capital Management LLC now owns 112,000 shares of the biotechnology company’s stock valued at $359,000 after buying an additional 90,474 shares during the period. Broadfin Capital LLC bought a new position in ADMA Biologics during the fourth quarter valued at about $3,538,000. Stonepine Capital Management LLC bought a new position in ADMA Biologics during the fourth quarter valued at about $217,000. Consonance Capital Management LP grew its position in ADMA Biologics by 164.3% during the fourth quarter. Consonance Capital Management LP now owns 3,367,635 shares of the biotechnology company’s stock valued at $10,810,000 after buying an additional 2,093,702 shares during the period. Finally, Morgens Waterfall Vintiadis & Co. Inc. bought a new position in ADMA Biologics during the fourth quarter valued at about $1,605,000. Institutional investors own 37.42% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply